AU2005311560A1 - MRI guided photodynamic therapy for cancer - Google Patents

MRI guided photodynamic therapy for cancer Download PDF

Info

Publication number
AU2005311560A1
AU2005311560A1 AU2005311560A AU2005311560A AU2005311560A1 AU 2005311560 A1 AU2005311560 A1 AU 2005311560A1 AU 2005311560 A AU2005311560 A AU 2005311560A AU 2005311560 A AU2005311560 A AU 2005311560A AU 2005311560 A1 AU2005311560 A1 AU 2005311560A1
Authority
AU
Australia
Prior art keywords
contrast agent
delivery system
mri
magnetic resonance
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2005311560A
Other languages
English (en)
Inventor
Tianyi Ke
Zheng-Rong Lu
Anagha Viadya
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Utah Research Foundation Inc
Original Assignee
University of Utah Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Utah Research Foundation Inc filed Critical University of Utah Research Foundation Inc
Publication of AU2005311560A1 publication Critical patent/AU2005311560A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/146—Peptides, e.g. proteins the peptide being a polyamino acid, e.g. poly-lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Radiology & Medical Imaging (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Laser Surgery Devices (AREA)
  • Radiation-Therapy Devices (AREA)
AU2005311560A 2004-12-03 2005-12-02 MRI guided photodynamic therapy for cancer Abandoned AU2005311560A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63325504P 2004-12-03 2004-12-03
US60/633,255 2004-12-03
PCT/US2005/044012 WO2006060797A2 (en) 2004-12-03 2005-12-02 Mri guided photodynamic therapy for cancer

Publications (1)

Publication Number Publication Date
AU2005311560A1 true AU2005311560A1 (en) 2006-06-08

Family

ID=36565853

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005311560A Abandoned AU2005311560A1 (en) 2004-12-03 2005-12-02 MRI guided photodynamic therapy for cancer

Country Status (9)

Country Link
US (1) US20090076571A1 (https=)
EP (1) EP1830879B1 (https=)
JP (1) JP2008522666A (https=)
KR (1) KR20070086803A (https=)
AT (1) ATE485836T1 (https=)
AU (1) AU2005311560A1 (https=)
CA (1) CA2589881A1 (https=)
DE (1) DE602005024437D1 (https=)
WO (1) WO2006060797A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE465205T1 (de) 2005-12-05 2010-05-15 Nitto Denko Corp Polyglutamat-aminosäure-konjugate und verfahren
US20080181852A1 (en) * 2007-01-29 2008-07-31 Nitto Denko Corporation Multi-functional Drug Carriers
JP2010526159A (ja) * 2007-04-10 2010-07-29 日東電工株式会社 多機能性ポリグルタミン酸塩薬物担体
US20080279778A1 (en) * 2007-05-09 2008-11-13 Nitto Denko Corporation Polyglutamate conjugates and polyglutamate-amino acid conjugates having a plurality of drugs
WO2009055542A1 (en) * 2007-10-26 2009-04-30 University Of Utah Research Foundation Use of mri contrast agents for evaluating the treatment of tumors
EP2440247B1 (en) * 2009-06-12 2017-03-08 Erasmus University Medical Center Rotterdam Targeted nano-photomedicines for photodynamic therapy of cancer
WO2013119957A1 (en) * 2012-02-10 2013-08-15 Aidan Research And Consulting, Llc Weight reduction through inactivation of gastric orexigenic mediator producing cells
TW201514188A (zh) * 2013-03-13 2015-04-16 Lantheus Medical Imaging Inc 製備釓磷維塞三鈉單水合物之方法
CN114870014B (zh) * 2022-05-18 2023-07-07 南京邮电大学 一种多功能抗肿瘤高分子药物及其制备方法和用途
WO2025160349A1 (en) * 2024-01-25 2025-07-31 Ovokaitys Todd Frank Methods and systems for improving photodynamic therapy by increasing depth of penetration without concurrently increasing energy deposition

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5594136A (en) * 1989-12-21 1997-01-14 Pharmacyclics, Inc. Texaphyrin solid supports and devices
WO1998026747A2 (en) * 1996-12-17 1998-06-25 Terman David S Superantigen based methods and compositions for treatment of diseases
DE19831217A1 (de) * 1998-07-03 2000-01-05 Schering Ag Neue Porphyrinderivate, diese enthaltende pharmazeutische Mittel und ihre Verwendung in der photodynamischen Therapie und MRI-Diagnostik
US6534040B2 (en) * 1999-12-23 2003-03-18 Health Research, Inc. Chlorin and bacteriochlorin-based aminophenyl DTPA and N2S2 conjugates for MR contrast media and radiopharmaceuticals
WO2002087632A1 (en) * 2001-05-02 2002-11-07 Metaprobe, Inc. High throughput screening methods using magnetic resonance imaging agents

Also Published As

Publication number Publication date
EP1830879B1 (en) 2010-10-27
JP2008522666A (ja) 2008-07-03
WO2006060797A3 (en) 2006-08-24
EP1830879A2 (en) 2007-09-12
US20090076571A1 (en) 2009-03-19
EP1830879A4 (en) 2008-09-17
WO2006060797A2 (en) 2006-06-08
DE602005024437D1 (de) 2010-12-09
KR20070086803A (ko) 2007-08-27
ATE485836T1 (de) 2010-11-15
CA2589881A1 (en) 2006-06-08

Similar Documents

Publication Publication Date Title
Zhu et al. Hyperbranched polymers for bioimaging
Liang et al. Theranostic porphyrin dyad nanoparticles for magnetic resonance imaging guided photodynamic therapy
Sun et al. In vivo MRI detection of gliomas by chlorotoxin‐conjugated superparamagnetic nanoprobes
JP5237821B2 (ja) ポリグルタミン酸−アミノ酸結合体および方法
Garimella et al. Multivalent, high-relaxivity MRI contrast agents using rigid cysteine-reactive gadolinium complexes
Lu et al. Poly (l-glutamic acid) Gd (III)-DOTA conjugate with a degradable spacer for magnetic resonance imaging
Liu et al. Photosensitizer-conjugated redox-responsive dextran theranostic nanoparticles for near-infrared cancer imaging and photodynamic therapy
Huang et al. Chlorotoxin-modified macromolecular contrast agent for MRI tumor diagnosis
Li et al. A photosensitizer-conjugated magnetic iron oxide/gold hybrid nanoparticle as an activatable platform for photodynamic cancer therapy
Vaidya et al. Contrast enhanced MRI‐guided photodynamic therapy for site‐specific cancer treatment
US20110110866A1 (en) Elastin-like polypeptide and gadolinium conjugate for magnetic resonance imaging
Vaidya et al. Contrast-enhanced MRI-guided photodynamic cancer therapy with a pegylated bifunctional polymer conjugate
Zhang et al. Fluorinated porphyrin-based theranostics for dual imaging and chemo-photodynamic therapy
EP1830879B1 (en) Mri guided photodynamic therapy for cancer
Fu et al. Dual activatable self-assembled nanotheranostics for bioimaging and photodynamic therapy
Ke et al. Biodegradable cystamine spacer facilitates the clearance of Gd (III) chelates in poly (glutamic acid) Gd-DO3A conjugates for contrast-enhanced MR imaging
Wang et al. Noninvasive visualization of pharmacokinetics, biodistribution and tumor targeting of poly [N-(2-hydroxypropyl) methacrylamide] in mice using contrast enhanced MRI
JP5341879B2 (ja) 疎水性化合物及びポリアミノ酸複合体を含む組成物
US20120052015A1 (en) End-capped polymers
Wang et al. Enzyme-responsive copolymer as a theranostic prodrug for tumor in vivo imaging and efficient chemotherapy
Wang et al. Trifunctional polymeric nanocomposites incorporated with Fe3O4/iodine-containing rare earth complex for computed X-ray tomography, magnetic resonance, and optical imaging
Bai et al. Non-invasively evaluating therapeutic response of nanorod-mediated photothermal therapy on tumor angiogenesis
Zarabi et al. HPMA copolymer–doxorubicin–gadolinium conjugates: synthesis, characterization, and in vitro evaluation
Zu et al. Multi-arm star-branched polymer as an efficient contrast agent for tumor-targeted magnetic resonance imaging
Zu et al. PEGylated chitosan grafted with polyamidoamine-dendron as tumor-targeted magnetic resonance imaging contrast agent

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period